Oxford Lane Capital Corp. Announces Net Asset Value and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
141
Oxford Lane Capital Corp. Announces Net Asset Value and Selected Financial Results as of March 31, 2017

GREENWICH, CT--(Marketwired - May 17, 2017) - Oxford Lane Capital Corp. ("Oxford Lane," "Fund," "we," "us" or "our") ( NASDAQ : OXLC ) ( NASDAQ : OXLCO ) ( NASDAQ : OXLCN ) announced today the following financial results and related information:

  • Net asset value per share as of March 31, 2017 stood at $10.20 compared with a net asset value per share at December 31, 2016 of $10.74.
  • Net investment income, calculated in accordance with generally accepted accounting principles ("GAAP"), was approximately $9.8 million, or approximately $0.45 per share, for the quarter ended March 31, 2017 and approximately $30.1 million, or approximately $1.51 per share, for the year ended March 31, 2017.
  • Our core net investment income ("Core NII") was approximately $9.3 million, or approximately $0.43 per share, for the quarter ended March 31, 2017, and approximately $54.1 million, or approximately $2.72 per share, for the year ended March 31, 2017.
    • Core NII represents net investment income adjusted for additional cash distributions received, or entitled to be received (if any, in either case), on our collateralized loan obligation ("CLO") equity investments. ( See additional information under "Supplemental Information Regarding Core Net Investment Income" below ).
    • While our experience has been that cash flow distributions have historically represented useful indicators of our CLO equity investments' annual taxable income, we believe that current and future cash flow distributions may provide less useful indications as to the final determination of taxable income with respect to our CLO equity investments.
  • Total investment income, calculated in accordance with GAAP, amounted to approximately $17.3 million for the quarter ended March 31, 2017.
    • For the quarter ended March 31, 2017, we recorded GAAP investment income from our portfolio as follows:
      • approximately $16.7 million from our CLO equity investments,
      • approximately $0.3 million from our CLO debt investments, and
      • approximately $0.3 million from other sources.
    • The weighted average yield of our CLO debt investments at current cost was approximately 9.6% as of March 31, 2017.
    • The weighted average effective yield of our CLO equity investments at current cost was approximately 19.4% as of March 31, 2017.
    • The weighted average cash yield of our CLO equity investments at current cost was approximately 22.4% as of March 31, 2017.
  • Net increase in net assets from operations was approximately $0.8 million, or approximately $0.04 per share, for the quarter ended March 31, 2017, and approximately $105.2 million, or approximately $5.28 per share, for the year ended March 31, 2017, including:
    • Net investment income of approximately $9.8 million and $30.1 million for the quarter ended March 31, 2017, and for the year ended March 31, 2017, respectively;
    • Net realized losses of approximately $2.4 million and $5.6 million for the quarter ended March 31, 2017 and for the year ended March 31, 2017, respectively; and
    • Net unrealized depreciation of approximately $6.7 million and unrealized appreciation of approximately $80.7 million for the quarter ended March 31, 2017 and for the year ended March 31, 2017, respectively.
  • During the quarter ended March 31, 2017, we made additional CLO equity investments of approximately $91.1 million.
  • During the quarter ended March 31, 2017, we received approximately $68.5 million from sales and repayments on our CLO investments.
  • During the quarter ended March 31, 2017, we issued a total of 1,281,912 shares of common stock pursuant to an "at-the-market" offering, resulting in net proceeds of approximately $14.4 million after deducting the sales agent's commissions and offering expenses.
  • During the quarter ended March 31, 2017, we issued a total of 600,000 shares of our Series 2023 Term Preferred Shares and 1,300 shares of our Series 2024 Term Preferred Shares pursuant to an "at-the-market" offering, resulting in aggregate net proceeds of approximately $14.9 million after deducting the sales agent's commissions and offering expenses.
  • Our Board of Directors has previously declared the following distributions on our common stock:
             
Quarter Ending   Record Date   Payment Date   Amount Per Share
June 30, 2017   June 16, 2017   June 30, 2017   $0.40
September 30, 2017   September 15, 2017   September 29, 2017   $0.40
             
  • These distributions reflect our operating performance during the quarter ended March 31, 2017, and our projections of the impact of the recent rise in the 3-month LIBOR (and the corresponding loss of the benefit from LIBOR floors) and compression in corporate loan spreads on our taxable income in 2017. We note that all but one of our CLO equity positions made full distributions in the quarter ended March 31, 2017. Going forward, we intend to declare and pay special distributions to our shareholders on an as-needed basis, in order to comply with our income distribution requirements as a regulated investment company. 

Our Board of Directors has also declared the required monthly dividends on our Series 2023 Term Preferred Shares and Series 2024 Term Preferred Shares (each, a "Share"), as follows:

           
  Per Share Dividend Amount Declared   Record Dates   Payment Dates
           
Series 2023 $0.15625   June 16, July 17, August 17   June 30, July 31, August 31
           
Series 2024 $0.16930   June 16, July 17, August 17   June 30, July 31, August 31
           

In accordance with their terms, each of the Series 2023 Term Preferred Shares and Series 2024 Term Preferred Shares will pay a monthly dividend at a fixed rate of 7.50% and 8.125%, respectively, of the $25.00 per share liquidation preference, or $1.875 and $2.03125 per share per year, respectively. This fixed annual dividend rate is subject to adjustment under certain circumstances, but will not in any case be lower than 7.50% and 8.125% per year, respectively, for each of the Series 2023 Term Preferred Shares and Series 2024 Term Preferred Shares.

Supplemental Information Regarding Core Net Investment Income

On a supplemental basis, we provide information relating to core net investment income, which is a non-GAAP measure. This measure is provided in addition to, but not as a substitute for, net investment income determined in accordance with GAAP. Our non-GAAP measures may differ from similar measures by other companies, even if similar terms are used to identify such measures. Core net investment income represents net investment income adjusted for additional cash distributions received, or entitled to be received (if any, in either case), on our CLO equity investments.

Income from investments in the "equity" class securities of CLO vehicles, for GAAP purposes, is recorded using the effective interest method based upon an effective yield to the expected redemption utilizing estimated cash flows compared to the cost, resulting in an effective yield for the investment; the difference between the actual cash received or distributions entitled to be received and the effective yield calculation is an adjustment to cost. Accordingly, investment income recognized on CLO equity securities in the GAAP statement of operations differs from the cash distributions actually received by us during the period (referred to below as "CLO equity adjustments").

Further, in order to continue to qualify to be taxed as a regulated investment company ("RIC"), we are required, among other things, to distribute at least 90% of our investment company taxable income annually. Therefore, core net investment income may provide a better indication of estimated taxable income for a reporting period than does GAAP net investment income, although we can offer no assurance that will be the case as the ultimate tax character of our earnings cannot be determined until tax returns are prepared after the end of a fiscal year. We note that these non-GAAP measures may not be useful indicators of taxable earnings, particularly during periods of market disruption and volatility. 

The following table provides a reconciliation of net investment income to core net investment income for the three months ended March 31, 2017:

           
    Three Months Ended     Year Ended
    March 31, 2017     March 31, 2017
          Per Share         Per Share
Amount     Amounts     Amount   Amounts
Net investment income   $ 9,834,904     $ 0.451     $ 30,142,425   $ 1.512
CLO equity adjustments     (506,665 )     (0.024 )     24,001,621     1.204
Core net investment income   $ 9,328,239     $ 0.427     $ 54,144,046   $ 2.716
                             

A presentation containing further detail regarding our quarterly results of operations has been posted to our website under the Investor Relations section at oxfordlanepresentation

We will host a conference call to discuss our fourth fiscal quarter results today, Wednesday, May 17, 2017 at 10:00 AM. Please call 1-844-792-3730 to participate. A replay of the call will be available for 30 days. If you are interested in hearing the replay, please dial 1-877-344-7529. The replay passcode is 10107563.

About Oxford Lane Capital Corp.

Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company. It currently seeks to achieve its investment objective of maximizing risk-adjusted total return by investing in securitization vehicles which, in turn, primarily invest in senior secured loans made to companies whose debt is unrated or is rated below investment grade.

Forward-Looking Statements

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward-looking statements. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors are identified from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect subsequent events, unless required to do so by law.

Contact: Bruce Rubin 203-983-5280

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading

Top 5 Most Recently Viewed Articles

Red Pine Unveils Exciting Gold Discoveries at Wawa Project

Updated Category News Views 177

Red Pine Exploration's Impressive Drilling Results Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) is thrilled to announce outstanding results from its ongoing drilling program at the Wawa Gold Project. This Canadian gold exploration company has executed a comprehensive drilling initiative, totaling 2,793 meters across three drill holes, aiming to unlock the full...

Continue Reading
Silver's Backwardation: What It Means for Investors Today

Updated Category News Views 447

Understanding Silver's Current Market Dynamics Recently, silver's futures market revealed a significant shift, entering a state of backwardation not seen for four decades. This phenomenon indicates that the short-term contract price is considerably higher than longer-term futures, reflecting a dramatic demand for immediate physical silver. The difference of $2.88...

Continue Reading
PGIM High Yield Funds Announce Monthly Distributions

Updated Category News Views 508

PGIM Funds Unveil Distribution Plans for Shareholders NEWARK, N.J.--PGIM High Yield Bond Fund, Inc. (NYSE: ISD), PGIM Global High Yield Fund, Inc. (NYSE: GHY), and PGIM Short Duration High Yield Opportunities Fund (NYSE: SDHY) have announced their monthly distributions for December 2024, January, and February 2025. This initiative signifies their commitment to delivering...

Continue Reading
Investors Urged to Act as Altimmune Faces Legal Challenges

Updated Category News Views 156

Important Legal Investigations Concerning Altimmune, Inc. Faruqi & Faruqi, LLP is currently investigating potential claims on behalf of investors who may have suffered financial losses related to Altimmune, Inc. (NASDAQ: ALT). Investors who acquired securities of Altimmune should pay close attention to this matter, as there are critical developments that could affect...

Continue Reading
Conejo Valley Unified Faces Lawsuits Over Assault Inaction

Updated Category News Views 6

Legal Scrutiny Hits Conejo Valley Unified In what feels like a never-ending cycle of educational mishaps, Conejo Valley Unified School District and its Westlake High School find themselves under the harsh spotlight of the legal system. Two lawsuits filed in Ventura County Superior Court are laying bare some serious accusations against them. Former students, using the...

Continue Reading